Class / Patent application number | Description | Number of patent applications / Date published |
424177100 | Reduced antigenicity, reduced ability to bind complement, or reduced numbers of activated complement components (e.g., free from aggregated, denatured, fragmented, or polymerized immunoglobulins; free from proteolytic enzymes, etc.) | 12 |
20090196880 | Cancer treatment using humanized antibodies that bind to EphB4 - In certain embodiments, this application provides humanized antibodies that bind to the EphB4 protein as well as uses of the antibodies for therapeutic purposes. | 08-06-2009 |
20110293638 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 12-01-2011 |
20120093839 | NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF - In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomelic counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided. | 04-19-2012 |
20130022625 | Stabilized Antibody-Containing Liquid Formulations - An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage. | 01-24-2013 |
20130058961 | METHOD FOR REDUCING THE THROMBOEMBOLIC POTENTIAL OF A PLASMA-DERIVED IMMUNOGLOBULIN COMPOSITION - The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting the leading portion of a cation exchange eluate. The present invention also provides immunoglobulin composition having reduced levels of amidolytic activity, Factor XI, and/or Factor XIa, and/or ACA content. | 03-07-2013 |
20130078264 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 03-28-2013 |
20130195897 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 08-01-2013 |
20140044742 | METHOD FOR PREPARING A DEPLETED PLASMA MATERIAL CONSISTING OF ONE OR MORE THROMBOGENIC FACTORS - The invention concerns a method for preparing a plasma product depleted of one or more thrombogenic factors, comprising the combination of at least two steps chosen from among an ethanol fractionation step, a filtration-adsorption step, a precipitation step with caprylic acid and a chromatography step on ion exchange resin. | 02-13-2014 |
20140072585 | NOVEL PURIFICATION OF ANTIBODIES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY - Disclosed herein are compositions and methods for purifying antibody products from a sample matrix. In particular, the present invention relates to compositions and methods for purifying antibody products employing hydrophobic interaction chromatography media. In certain embodiments, the invention provides a method for reducing process-related impurities (e.g., host cell proteins), as well as product-related substances, including molecular weight variants (e.g., aggregates and fragments of the antibody product). | 03-13-2014 |
20140141021 | METHOD FOR PREPARING A CONCENTRATE OF POLYVALENT IMMUNOGLOBULIN - The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained. | 05-22-2014 |
20140154270 | PURIFICATION OF NON-HUMAN ANTIBODIES USING KOSMOTROPIC SALT ENHANCED PROTEIN A AFFINITY CHROMATOGRAPHY - The present invention is directed to methods for purifying a non-human antibody, or antigen binding portion thereof, exhibiting weak binding strength and low binding capacity for Protein A chromatography media. In one aspect, a kosmotropic salt solution is employed to promote the hydrophobic interaction between the non-human antibody, or antigen binding portion thereof, and the Protein A ligand, thereby enhancing the binding of the non-human antibody, or antigen binding portion thereof, to the Protein A chromatography media. In another aspect, the concentration of the non-human antibody, or antigen binding portion thereof, in a sample comprising the antibody, or antigen binding portion thereof, exposed to a Protein A chromatography media is increased to enhance the binding of the non-human antibody, or antigen binding portion thereof, on the Protein A chromatography media. | 06-05-2014 |
20160058863 | LOW VISCOSITY CONCENTRATED PROTEIN DISPERSIONS - Disclosed herein are, inter alia, low viscosity dispersions comprising proteins and viscosity lowering agents; pharmaceutical compositions comprising low viscosity dispersions; and methods of making and using the pharmaceutical compositions and low viscosity dispersions. | 03-03-2016 |